- Details
- Radiation Oncologist, Juan Galvis Serrano joins Phillip Koo for a presentation and discussion on radiotherapy guided by PET PSMA. We are still defining its role in guiding radiotherapy treatment plans but PET-PSMA has shown a higher sensitivity than conventional methods with stable sensitivity and higher specificity. Dr. Galvis Serrano shares a study conducted at his institution with prostate canc...
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine article titled "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study." The authors' findings support the new EAU classification for biochemically recurrent prostate cancer (BCR), that BCR high-risk groups have...
|
- Details
- David Schuster joins Phillip Koo in discussing the results of SPOTLIGHT, a phase 3, prospective, multicenter study assessing the detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence. The single-arm SPOTLIGHT imaging study, conducted in the United States and Europe evaluates the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspect...
|
- Details
- Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...
|
- Details
- Philip Koo, Oliver Sartor, and Neal Shore discuss the revolutionary impact of PSMA PET in the detection and management of prostate cancer. The experts explain the approved indications of PSMA PET agents PSMA 11 and PYLARIFY, emphasizing their transformative role in managing high-risk and intermediate-risk prostate cancer patients. Drs. Shore and Sartor detail how these imaging technologies inform...
|
- Details
- Alicia Morgans and Tanya Dorff, discuss the updates to the NCCN guidelines since the approval of PSMA PET CT molecular imaging agents. They discuss new guidance based on the FDA-approved indications in the labels for the use of molecular imaging agents for detecting prostate cancer when PSA levels are still relatively low and when PSA levels are rising. Biographies: Tanya B. Dorff, MD., is an asso...
|
- Details
- In this Society of Nuclear Medicine and Molecular Imaging- Special Session during the 2021 LUGPA CME presentations, Dr Steven Rowe discusses a number of different scenarios that we might encounter clinically where conventional imaging is clearly being replaced by PSMA based imaging. In the last part of his talk, Dr. Rowe focuses on some future directions where PSMA PET may have some interesting th...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...
|
- Details
- In a conversation hosted by Phillip Koo, Sam Mehr outlines the intricacies of establishing a theranostics program within a medical oncology practice. Dr. Mehr discusses the "NCS/Nebraska Cancer Specialists model," which aims to offer targeted nuclear therapy through a patient-centered approach. He emphasizes the importance of a multidisciplinary team, including a program director who serves as the...
|
- Details
- The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...
|